FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain (PR Newswire via Yahoo! Finance)
Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

Relapsed Ovarian Cancer - Submitted New Drug Application To FDA For Trabectedin (Medical News Today)
PharmaMar announced today that Ortho Biotech Products, L.P. has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer (ROC).

FDA Approves Tapentadol Immediate-Release Tablets For Relief Of Moderate To Severe Acute Pain (Medical News Today)
Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option. Today, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the U.S. Food and Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults 18 years of age or older.